

A Champion of Host Defense: A Generic Large-Scale Cause for Platelet Dysfunction and Depletion in Infection

Martin J. Page, BSc (Hons)¹  Ethersia Pretorius, PhD¹ 

¹Department of Physiological Sciences, Stellenbosch University, Stellenbosch, South Africa

Semin Thromb Hemost 2020;46:302–319.

Address for correspondence Ethersia Pretorius, PhD, Department of Physiological Sciences, Faculty of Science, Stellenbosch University, Private Bag X1 Matieland, Stellenbosch, 7602, South Africa (e-mail: resiap@sun.ac.za).

Abstract

Thrombocytopenia is commonly associated with sepsis and infections, which in turn are characterized by a profound immune reaction to the invading pathogen. Platelets are one of the cellular entities that exert considerable immune, antibacterial, and antiviral actions, and are therefore active participants in the host response. Platelets are sensitive to surrounding inflammatory stimuli and contribute to the immune response by multiple mechanisms, including endowing the endothelium with a proinflammatory phenotype, enhancing and amplifying leukocyte recruitment and inflammation, promoting the effector functions of immune cells, and ensuring an optimal adaptive immune response. During infection, pathogens and their products influence the platelet response and can even be toxic. However, platelets are able to sense and engage bacteria and viruses to assist in their removal and destruction. Platelets greatly contribute to host defense by multiple mechanisms, including forming immune complexes and aggregates, shedding their granular content, and internalizing pathogens and subsequently being marked for removal. These processes, and the nature of platelet function in general, cause the platelet to be irreversibly consumed in the execution of its duty. An exaggerated systemic inflammatory response to infection can drive platelet dysfunction, where platelets are inappropriately activated and face immunological destruction. While thrombocytopenia may arise by condition-specific mechanisms that cause an imbalance between platelet production and removal, this review evaluates a generic large-scale mechanism for platelet depletion as a repercussion of its involvement at the nexus of responses to infection.

Keywords

- ▶ platelets
- ▶ virus
- ▶ bacteria
- ▶ thrombocytopenia
- ▶ immune response

Infections, both bacterial and viral, are associated with a profound immune response to the infecting pathogen. Platelets are important contributors to the multifaceted response to infection, where they have the ability to modulate various immune cells. Platelets engage the immune system through direct cell-to-cell interaction and through the release of various soluble mediators.^{1–5} Furthermore, platelets participate in the interaction between pathogens and host defense.^{6–12} In the absence of platelets, bacteremia, tissue damage, and

mortality are greatly enhanced.^{13–15} Similarly, thrombocytopenia is associated with a dysregulated host response and worse outcomes in sepsis patients.^{16,17} Platelets are also active participants in the host response to viruses, and have been shown to be protective in viral infections.^{18–20}

Platelets possess receptors that allow them to survey for danger signals from pathogens (pathogen-associated molecular patterns; PAMPs) and cell damage (damage-associated molecular patterns; DAMPs), and trigger hemostatic and

Issue Theme Acquired Platelet Dysfunction—Laboratory and Clinical Implications; Guest Editors: Anne-Mette Hvas, MD, PhD, Julie Brogaard Larsen, MD, PhD, and Leonardo Pasalic, MBBS, PhD.

Copyright © 2020 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel: +1(212) 760-0888.

DOI <https://doi.org/10.1055/s-0040-1708827>.
ISSN 0094-6176.

published online
April 12, 2020

License terms



inflammatory responses against bacterial and viral infections.^{3,21,22} During infection, the platelet is activated, mobilized, and actively participates in the resultant hemostatic and inflammatory responses. These signaling processes involve many feedback loops that self-amplify initial activation,²³ and platelets can manifest dysfunction even in cases where no bacteremia is present.¹⁰ These processes are irreversible and undoubtedly lead to consumption of the platelet. Activation of platelets leads to their consumption into aggregates with other platelets, leukocytes, and the endothelium.²⁴ Platelets with bound antibody are targets of phagocytes, and platelets with a bacterial or viral load are sequestered and also cleared from the circulation. Further, pathogenic compounds induce apoptosis and cytotoxic effects in platelets.²⁵ In this sense, activated platelets and platelets interacting with pathogens have shortened survival spans and experience increased destruction. The outcome for the patient will be a decrease in normal circulating platelets, and if this manifests widely enough it can be measured as thrombocytopenia.^{3,25}

Other mechanisms of platelet decline in infection exist and include the formation of autoantibodies against platelet surface proteins, which leads to clearance of immunoglobulin G (IgG)-coated platelets by the reticuloendothelial system,^{26,27} as well as by impaired platelet production in the bone marrow,^{3,6} among others.⁶ However, a general view of platelet destruction is the simple characteristic that their involvement in thrombotic, hemostatic, immune, and host defense responses is irreversible. Even if platelets are positive contributors to the host response against invading pathogens, they can become dysfunctional, especially in the context of an excessive and unbalanced systemic inflammatory response.^{16,28} Indeed, the dysfunctional state of thrombocytopenia is commonly associated with sepsis and infections.^{3,29-31}

The focus of the current review is platelets and their role in infection. We will examine the interaction of platelets, their receptors, and secretory product with bacteria and viruses, and discuss how this may contribute to platelet dysfunction and ultimately lead to thrombocytopenia. ► **Fig. 1** provides the




Fig. 1 Layout of the review. During infection, inflammatory stimuli, and the presence of bacteria, viruses and their products mobilize platelets to exert their immune, antibacterial, and antiviral actions. However, these processes can also lead to platelet dysfunction and ultimately depletion.

rationale of this review and ► **Table 1** lists the abbreviations used in this article.

Platelet and the Immune Response to Infections

A common feature of many infections, both viral and bacterial, is a systemic inflammatory response that involves a dysregulated proinflammatory biomarker presence in the circulation.^{3,5,32} These biomarkers may include cytokines (e.g., interleukins [ILs], tumor necrosis factor [TNF]- α , and interferons) but also molecules originating from bacteria and viruses themselves (e.g., proteases, ribonucleic acid [RNA], and membrane components like lipopolysaccharide [LPS], lipoteichoic acid [LTA], and viral glycoproteins). The presence of such circulating biomarkers has profound agonistic effects on platelets.

Platelets contribute to the thromboinflammatory response through the plethora of membrane and cytosolic molecules that they express and release, which possess hemostatic, immunomodulatory, and inflammatory activity.¹⁻⁴ Platelets possess receptors that enable pathogen sensing, and which allow platelets to regulate leukocytes and other cells at the site of infection. During platelet activation, degranulation leads to the surface expression of receptors and the release of abundant proinflammatory mediators, which contribute to numerous signaling events.¹⁻⁵ Platelets also adhere and aggregate to other platelets and to endothelial cells, leukocytes, and erythrocytes.^{5,9,24} This response is also characteristic during bacterial and viral infections, and can be induced by pathogens directly.³³ This section describes the role of platelets in the immune response. See ► **Fig. 2** for a general overview of platelet receptors and secretory products.

Platelet–Endothelium Interactions: Endowing a Proinflammatory Phenotype

Endothelial activation markers are raised during infection, and are associated with a thrombotic state.³⁴ During activation, platelets can bind to the endothelium.²⁴ This especially occurs upon endothelial damage due to trauma or microbial colonization,³⁵ as well as in viral infections.³⁶ Platelets become activated during the adhesion process, and the inflammatory and mitogenic substances that are released alter the chemotactic, adhesive, and proteolytic properties of endothelial cells.³⁷ Platelet adhesion therefore endows the endothelium with a proinflammatory phenotype.²⁴ Moreover, platelets that are bound to the endothelium can form a bridging connection with circulating leukocytes.²⁴ Overall, these mechanisms amplify and facilitate leukocyte recruitment and enhance inflammation. ► **Fig. 3** provides an overview of the contact between platelets and cells at the vascular wall to emphasize the involvement of platelets in multiple interactions at the vessel wall.

Platelet–Leukocyte Interactions: Promoting Immune Cell Effector Functions against Pathogens

Interactions between platelets and leukocytes are important for the regulation of the immune response and for the clearance of infectious agents. By binding and activating leukocytes, platelets promote their effector functions. Coordination of

Table 1 List of abbreviations

Abbreviation	Full term	Synonyms
α Ib β 3		GPIIb/IIIa
α M β 2	Macrophage-1 antigen	CD11b/CD18, CR3; Mac-1
cAMP	Cyclic adenosine monophosphate	
CAR receptor	Coxsackievirus and adenovirus receptor	
(s)CD40L	(Soluble) CD40 ligand	CD154
cGMP	Cyclic guanosine monophosphate	
CR2	Complement receptor 2	CD21, C3dR
CR3	Complement receptor 3	α M β 2, CD11b/CD18, Mac-1
CR4	Complement receptor 4	α x β 2, CD11c/CD18
DAMP	Damage-associated molecular pattern	
DNA	Deoxyribonucleic acid	
Eap	Extracellular adherence protein	
Efb	Extracellular fibrinogen binding protein	
Fc γ RIIa	Low affinity immunoglobulin gamma Fc region receptor II-a	CD32
GPIb	Glycoprotein Ib	CD42
GPVI	Glycoprotein VI	
HIV	Human immunodeficiency virus	
HLA-DR	Human leukocyte antigen—DR isotype	
HRgpA	Recombinant gingipain R1 protease (high molecular mass form)	
Ig	Immunoglobulin	
IL	Interleukin	
LCMV	Lymphocytic choriomeningitis virus	
LPS	Lipopolysaccharide	
LTA	Lipoteichoic acid	
MyD88	Myeloid differentiation primary response 88	
NET	Neutrophil extracellular trap	
P-selectin		CD62P, GMP-140, PADGEM
PAF	Platelet-activating factor	
PAMP	Pathogen-associated molecular pattern	
PAR	Protease-activated receptor	
PF4	Platelet factor 4	CXCL4
PKG	cGMP-dependent protein kinase	
PSGL-1	P-selectin glycoprotein ligand-1	CD162
RANTES	Regulated on activation, normal T-cell expressed and secreted	CCL5
RgpB	Recombinant gingipain R2 protease	
RNA	Ribonucleic acid	
ROS	Reactive oxygen species	
SSL	Staphylococcal superantigen-like	
TLR	Toll-like receptor	
TNF	Tumor necrosis factor	
TREM-1(L)	Triggering receptor expressed on myeloid cells 1 (ligand)	CD354



Fig. 2 General platelet structure. Platelets express various receptors that allow them to detect danger signals and engage other cells. Platelets are activated by various agonists that interact with surface receptors. Platelets are also replete with secretory granules that store bioactive molecules, which are released into the circulation or translocate to the surface upon platelet activation. These characteristics allow platelets to communicate and modulate the functions of other cells, and trigger hemostatic, inflammatory, and host defense responses against infections (created with <https://biorender.com/>). ADP, adenosine diphosphate; CAR, coxsackievirus and adenovirus receptor; CCR/CXCR, chemokine receptor; CLEC, C-type lectin-like receptor; CR, complement receptor; DC-SIGN, dendritic cell-specific ICAM-grabbing nonintegrin; FcγRIIIa, low-affinity immunoglobulin gamma Fc region receptor II-a; gC1qR, receptor for the globular heads of C1q; JAM, junction adhesion molecule; MCP, monocyte chemoattractant protein; MHC, major histocompatibility complex; MIP, macrophage inflammatory protein; PAFR, platelet-activating factor receptor; PAR, protease-activated receptor; PDGF, platelet-derived growth factor; PF, platelet factor; RANTES, regulated on activation, normal T-cell expressed and secreted; TGF, transforming growth factor; TLR, toll-like receptor; TNSF14, tumor necrosis factor superfamily member 14; TREM, triggering receptor expressed on myeloid cells; vWF, von Willebrand factor.

immune cells by platelets ensures a rapid and targeted host defense response. In a dynamic cross-talk, leukocytes can also release factors that modulate platelet function.

Platelets adhere to phagocytes and deliver signals that enhance the killing of internalized pathogens. Platelets are able to modulate neutrophil responses where they enhance neutrophil phagocytosis in a process involving toll-like receptor (TLR) 2 and P-selectin/P-selectin glycoprotein ligand (PSGL)-1.³⁸ This was demonstrated for both *Aggregatibacter actinomycetemcomitans* and *Porphyromonas gingivalis*.³⁸ Platelets can augment the respiratory burst in neutrophils in response to opsonized *Escherichia coli* and *Staphylococcus aureus*.³⁹ Platelet–neutrophil complexes have more activated adhesion molecules, greater phagocytic ability, and greater toxic oxygen metabolites than noncomplexed neutrophils.⁴⁰ Activated platelets can also induce superoxide anion release

by monocytes and neutrophils through P-selectin.⁴¹ Soluble CD40 ligand (CD40L) further interacts with CD40 and $\alpha\text{M}\beta\text{2}$ on neutrophils to induce the adhesive functions of neutrophils as well as cause CD40-dependent reactive oxygen species (ROS) generation.⁴²

Additionally, the triggering receptor expressed on myeloid cells (TREM)-1 ligand is expressed on platelets and has been shown to induce neutrophil activation, and platelets enhance the neutrophil respiratory burst and release of IL-8 in a TREM-1-specific manner in the presence of LPS.⁴³ The TREM-1 receptor is an important receptor in the innate immune response as well as in severe sepsis where it amplifies the immune response to microbial products.⁴⁴ TREM-1 has also been shown to contribute to neutrophil activation in viral infections.⁴⁵

Furthermore, platelets induce the release of neutrophil extracellular traps (NETs), deoxyribonucleic acid (DNA) covered with various antimicrobial nuclear and granule-derived molecules⁴⁶ that ensnare and kill pathogens, in response to bacterial (septic) stimuli.^{39,47,48} This NET response has been documented in *E. coli* gram-negative sepsis and *S. aureus* gram-positive sepsis.⁴⁷ Platelets have further been shown to interact with neutrophils following viral challenge, leading to the release of NETs.^{49–51} NETs also deliver antiviral factors such as myeloperoxidase⁴⁶ and α -defensin,⁵⁰ and capture viruses and promote their elimination.⁵¹ **Fig. 4** provides an overview of the interactions between platelets and immune cells to emphasize the involvement of platelets in the immune response.

Platelet Involvement in Adaptive Immunity: Ensuring an Optimal Adaptive Response

Further to the innate immune response, platelets are also important for an optimal adaptive immune response. The periodontopathogens *A. actinomycetemcomitans* and *P. gingivalis* have been shown to induce expression of CD40L on human platelets via TLR2 and TLR4.⁵² Platelets can modulate B and T cell responses to microbial pathogens through CD40L, and are able to induce isotype switching by B cells and augment CD8⁺ T cell function.^{53,54} CD40L on platelets enable T cell priming and augment CD8⁺ T cell responses against bacterial pathogens by enhancing maturation signals to dendritic cells and lowering the threshold for cell activation^{55–57} (compare with reports that platelets can have an inhibitory effect on dendritic cells^{58,59}).

Platelet-mediated modulation of the adaptive immune system has also been shown to enhance protection against viral rechallenge.⁵³ Platelets expressing integrin β3 and CD40L are essential for lymphocytic choriomeningitis virus (LCMV) clearance by virus-specific cytotoxic T cells, and protect the host from virus-induced interferon- α/β lethal hemorrhage.¹⁸ Activated platelets can also contribute to immunopathology (e.g., liver damage) by accumulating virus-specific cytotoxic T cells at the site of inflammation in models of acute viral hepatitis.⁶⁰ Serotonin released from platelets is vasoactive and can further support viral persistence in the liver by reducing microcirculation, which aggravates virus-induced immunopathology in a model of LCMV-induced hepatitis.⁶¹

Platelets can further shuttle blood-borne gram-positive bacteria to splenic CD8 α^+ dendritic cells after the bacterium becomes associated to platelets via glycoprotein (GP)-Ib and




Fig. 3 Platelet interactions at the vascular wall. Platelet activation and adhesion to the vascular wall is facilitated by various receptor interactions with endothelial cells. An inflamed vessel wall will adopt a prothrombotic phenotype and release platelet binding and stimulating agents. The adhesion of platelets activates endothelial cells, and together with potent inflammatory mediators released by platelets induces the expression of integrins, adhesion molecules, and other receptors on the endothelial surface, as well as causes the endothelium to secrete chemokines and other mediators. Platelets similarly bind and activate leukocytes, contributing to leukocyte recruitment to the endothelium. In turn, leukocytes are activated and are able to adhere to the inflamed vessel, with platelets also serving as bridging connections between the endothelium and circulating leukocytes (created with <https://biorender.com/>). (Adapted from van Gils et al²⁴.) ADP, adenosine diphosphate; GM-CSF, granulocyte-macrophage colony-stimulating factor; ICAM, intercellular adhesion molecule; IL, interleukin; JAM, junction adhesion molecule; MCP, monocyte chemoattractant protein; MMP, matrix metalloproteinase; MTP1-MMP, membrane type-1 MMP; PF, platelet factor; PSGL, P-selectin glycoprotein ligand-1; RANTES, regulated on activation, normal T-cell expressed and secreted; ROS, reactive oxygen species; TNSF14(R), tumor necrosis factor superfamily member 14 (receptor); tPA, tissue plasminogen activator; TREM, triggering receptor expressed on myeloid cells; uPA, urokinase-type plasminogen activator; uPAR, urokinase receptor; VCAM, vascular cell adhesion protein; vWF, von Willebrand factor.




Fig. 4 Platelet interactions with immune cells. Platelets are important contributors to the multifaceted immune response to infection and have the ability to engage the immune system. Degranulation leads to the surface expression of receptors and the release of abundant proinflammatory mediators that regulate leukocytes at the site of infection. Platelets also modulate leukocytes involved in adaptive immunity. Ultimately, platelets promote the effector functions of immune cells and enable an optimal immune response (created with <https://biorender.com/>). IL, interleukin; MCP, monocyte chemoattractant protein; MHC, major histocompatibility complex; MIP, macrophage inflammatory protein; PAF, platelet-activating factor; PDGF, platelet-derived growth factor; PF, platelet factor; RANTES, regulated on activation, normal T-cell expressed and secreted; ROS, reactive oxygen species; TGF, transforming growth factor; TNF, tumor necrosis factor; Treg, regulatory T cell.

complement C3 to balance bacterial clearance with immune induction.⁶² Activated platelets also form aggregates with CD16⁺ inflammatory monocytes and human leukocyte antigen (HLA)-DR⁺ CD38⁺ memory T cells in human immunodeficiency virus (HIV) infection.⁷

Platelet-Derived Microparticles: Further Driving the Inflammatory Response

Activated platelets produce microparticles during bacterial^{63,64} and viral infection^{65,66} that contain both soluble (e.g., regulated on activation, normal T cell expressed and secreted [RANTES]) and surface mediators (e.g., P-selectin, GPIb, and α Ib β 3), which can exit the vasculature and enter tissues

where they are able to activate leukocytes to further drive the inflammatory response.^{67,68} For example, platelet microparticles enhance the expression of cell adhesion molecules such as leukocyte α M β 2 for monocyte adhesion,⁶⁹ and can mediate leukocyte activation⁷⁰ and leukocyte-leukocyte interactions.⁷¹ Microparticles promote platelet interaction with the endothelium by acting as a substrate for further platelet binding.⁷² Further, microparticles can deliver platelet-derived CD40L signals^{54,73} and activate dendritic cells.⁷⁴ Platelet microparticles also promote endothelial activation by secreting IL-1 β ,⁷⁵ and can deliver RANTES to the endothelium for monocyte recruitment.⁷⁶ Lastly, these microparticles can cause complement activation.⁷⁷

Platelet Interactions with Bacteria

Platelets are active role players in antimicrobial defense, and exhibit complex interactions with bacteria and viruses due to the variety of platelet receptors involved in pathogen recognition. Platelets are able to recognize, bind, and internalize pathogens to sequester and neutralize the pathogen. This section describes the interactions of platelets with bacteria, which are summarized in ►Fig. 5.

Platelet Receptors in Bacterial Pathogen Sensing

It has long been known that bacteria can cause platelet aggregation and degranulation.^{78,79} A diverse range of platelet receptors can mediate interactions with bacteria, including α IIb β 3, low-affinity immunoglobulin gamma Fc region receptor II-a (Fc γ RIIa), GPIb, complement receptors (CRs), and TLRs,^{80,81} either directly or indirectly through bridging molecules.^{11,12,81} Alternatively, products shed by bacteria⁸² may cause a platelet response independently of direct




Fig. 5 Platelet interactions with bacteria. Platelets are able to sense and bind bacteria through a variety of platelet receptors, and various bacterial products stimulate platelets, modulating their function. Platelets typically become activated and aggregate, but bacterial products may exert inhibitory actions or cause platelet destruction. Platelets additionally mediate antimicrobial actions by releasing microbicidal proteins, engulfing bacteria, and interacting with immune cells. These interactions further enhance the immune response and lead to platelet clearance (created with <https://biorender.com/>). C3, complement component 3; Eap, extracellular adherence protein; Efb, extracellular fibrinogen-binding protein; Fc γ RIIa, low-affinity immunoglobulin gamma Fc region receptor II-a; gC1qR, receptor for the globular heads of C1q; Ig, immunoglobulin; LPS, lipopolysaccharide; LTA, lipoteichoic acid; PAF(R), platelet-activating factor (receptor); PAR, platelet-activating factor; PLC, phospholipase C; Rgp, recombinant gingipain; ROS, reactive oxygen species; SSL, staphylococcal superantigen-like; TLR, toll-like receptor; vWF, von Willebrand factor.

Table 2 Platelet receptors that mediate bacterial adhesion and platelet activation

Bacteria	Bacterial component	Platelet receptors/host factors	References
<i>Borrelia burgdorferi</i>		α IIb β 3	182
<i>Chlamydia pneumoniae</i>		α IIb β 3	183
<i>Helicobacter pylori</i>		IgG-Fc γ RIIa, GPIb, vWF	184
<i>Porphyromonas gingivalis</i>	Hgp44	GPIb, IgG-Fc γ RIIa	185
<i>Streptococcus agalactiae</i>	FbsA	α IIb β 3, fibrinogen, IgG-Fc γ RIIa	186
<i>Staphylococcus aureus</i>	ClfA, ClfB, FnBPA, SdrE, SpA, IsdB	α IIb β 3, fibrinogen, fibronectin, IgG-Fc γ RIIa, complement gC1qR, thrombospondin, vWF	84,187–201
<i>Staphylococcus epidermidis</i>	SdrG	α IIb β 3, fibrinogen, IgG-Fc γ RIIa	202
<i>Streptococcus gordonii</i>	PadA, SspA/SspB, GspB/Hsa	α IIb β 3, GPIb, IgG-Fc γ RIIa	84,203–206
<i>Staphylococcus lugdunensis</i>	Fbl	Fibrinogen	207
<i>Streptococcus mitis</i>	PblA, PblB, lysin	α IIb β 3, fibrinogen, membrane ganglioside GD3	208,209
<i>Streptococcus oralis</i>		GPIb, IgG-Fc γ RIIa	84,210
<i>Streptococcus pneumoniae</i>	Pav, PspC/Hic	α IIb β 3, fibrinogen, IgG-Fc γ RIIa, thrombospondin, PAF receptor	84,211–213
<i>Streptococcus pyogenes</i>	M protein	α IIb β 3, fibrinogen, IgG-Fc γ RIIa	201,214
<i>Streptococcus sanguis</i>	SrpA	α IIb β 3, fibrinogen, IgG-Fc γ RIIa, GPIb	84,215–217

Abbreviations: Clf, clumping factor; FnBPA, fibronectin-binding protein A; IsdB, iron-regulated surface determinant B; PadA, platelet adherence protein A; PavB, pneumococcal adherence and virulence factor B; PspC, pneumococcal surface protein C; Sdr, serine-aspartate repeat protein; SpA, staphylococcal protein A; SrpA, serine-rich protein A; Ssp, stringent starvation protein; vWF, von Willebrand factor.

bacterial attachment to the platelet.¹⁰ Ultimately, engagement of receptors by bacteria and their products leads to common and species-specific intracellular signaling events in platelets.⁸³

► **Table 2** summarizes platelet receptors that mediate binding of bacteria to cause platelet activation and aggregation. A key mechanism for bacterial adhesion to platelets, which is described for various bacteria, involves α IIb β 3 integrin activation, the Fc γ RIIa receptor, and IgG,⁸⁴ where platelet factor (PF)-4 may potentiate further binding of additional bacteria by forming an immunocomplex with bacteria that bind through Fc γ RIIa.⁸⁵

Platelets also express C–C motif and C–X–C motif chemokine receptors such as CCR1, CCR2, CCR4, and CXCR4,⁸⁶ which can detect all four classes of chemokines (C, CC, CXC, and CX₃C). These receptors allow platelets to recognize and prioritize chemotactic signals and result in rapid vectoring of platelets to sites of infection.⁹ They are also involved in stimulating platelet adhesion, aggregation, and secretion.⁸⁷ Additionally, platelet activation leads to activation of the complement system,^{88,89} and platelets also express various complement receptors after activation such as CR2, CR3, CR4, C3aR, C5aR, cC1qR, and gC1qR.³ These may therefore serve as potential receptors for bacteria coated with complement factors, and lead to platelet aggregation.¹¹ Furthermore, an important class of receptors for pathogen sensing are TLRs, and platelets express numerous TLRs to detect the molecular features of microbes.^{21,90–92} Platelets express, among others, functional TLR4,⁹³ as well as the accessory component for LPS signaling, including CD14, MD2, and myeloid differentiation primary response (MyD)-88.⁹⁴

Bacterial Products Affect Platelet Functions

Platelets are able to respond to many bacterial products, and these products modulate platelet function.²⁵ LPS can stimulate platelet secretion of dense and α -granules through TLR4/MyD88 and cyclic guanosine monophosphate (cGMP)/cGMP-dependent protein kinase (PKG) signaling pathways.⁹⁴ This potentiates secretion-dependent integrin activation and platelet aggregation. Further to this, platelets recognize and discriminate between various isoforms of bacterial LPS and secrete differential cytokine profiles against these danger signals.^{95,96} LPS also induces sCD40L release from platelets⁹⁷ as well as ROS generation.⁹⁸ Some sources of LPS can activate TLR2,^{99–101} and this has also been implicated in LPS-induced cGMP elevation and platelet activation.⁹⁴ However, LPS is described as not always generating conventional platelet activation (e.g., typical P-selectin release from α -granules).²⁵ Bacterial structures from gram-positive bacteria such as lipoproteins, peptidoglycan, and LTA are TLR2 ligands, and also trigger platelet activation.^{92,102} TLR activation in platelets induces a thromboinflammatory response, including platelet aggregation, formation of platelet–leukocyte complexes, and ROS generation¹⁰³ as well as the elaboration of acute-phase reactants like TNF- α .⁹¹ However, studies have shown mixed effects of TLR2 agonists and LTA on platelet aggregation.^{104,105}

Platelets can migrate toward the chemotactic signal of bacterial N-formyl peptide by their receptors for this peptide.¹⁰⁶ The gingipain proteases HRgpA and RgpB from *P. gingivalis* activate platelet protease-activated receptor (PAR)-1 and PAR4, leading to platelet aggregation.^{107,108} *S. aureus* α -toxin also causes platelet activation and leads to

enhanced prothrombinase activity on the platelet surface.^{109,110} Staphylococcal superantigen-like (SSL)-5 from *S. aureus* additionally induces platelet activation via platelet receptors GPVI and GPIb,^{111,112} whereas the Panton–Valentine leukocidin toxin leads to platelet activation via neutrophil secretion products from damaged neutrophils.¹¹³

Another class of exotoxins from *S. aureus*, extracellular adherence protein (Eap) and extracellular fibrinogen-binding protein (Efb) fibrinogen-binding proteins, also interacts with platelets. On the one hand, Eap enhances α Ib β 3 integrin activation, granule secretion, and aggregation,¹¹⁴ whereas Efb inhibits platelet activation and aggregation^{115,116} and has powerful antiplatelet actions.¹¹⁷ *Staphylococcus aureus* enterotoxin B similarly inhibits platelet aggregation.¹¹⁸ LTA from *S. aureus* has also been reported to inhibit platelet activation through platelet-activating factor (PAF) receptor and raised cyclic adenosine monophosphate (cAMP),¹¹⁹ as well as to inhibit platelet aggregation,^{120–122} but may support platelet adhesion to *Staphylococcus epidermidis*.¹²³ Additional products released by *S. aureus* also have opposing functions on platelet aggregation. While staphylothrombin mediates fibrin formation that supports aggregation,¹²⁴ staphylokinase prevents aggregation by degrading fibrinogen.¹²⁵

Bacterial toxins can also cause platelet destruction. For example, α -toxin from *S. aureus* and α -hemolysin from *E. coli*¹²⁶ as well as peptidoglycan from *S. aureus*¹²⁷ can induce platelet apoptosis. Indeed, these pore-toxins stimulate disturbances in the platelet membrane and can be cytotoxic.^{3,128} *Escherichia coli* Shiga toxin causes downregulation of platelet CD47 expression, which leads to enhanced platelet activation and phagocytosis of platelets by macrophages.¹²⁹ Toxins such as pneumolysin from *Streptococcus pneumoniae*¹³⁰ and α -toxin from *S. aureus*¹³¹ can cause platelet lysis, whereas streptolysin O from *Streptococcus pyogenes*¹³² and phospholipase C from *Clostridium perfringens*¹³³ induce the formation of platelet–leukocyte complexes.

Platelets Mediate Antimicrobial Attack

A further function of platelets in bacterial infection is mediating antimicrobial attack. Platelets mediate some of their antimicrobial actions through the secretion of potent antimicrobial proteins from their α -granules.^{8,35} Moreover, platelets rapidly form clusters around bacteria that have been captured by Kupffer cells in the liver sinusoids (specialized macrophages in the liver), encasing the bacterium and facilitating its destruction.¹³ Further, sCD40L causes increased generation and release of reactive oxygen (e.g., superoxide) and nitrogen (e.g., nitric oxide) species by platelets, which assists in pathogen destruction.^{134,135}

Platelets are able to bind and endocytose/phagocytose bacteria through engulfing endosome-like vacuoles that are formed by membrane endocytosis and become the site of α -granule release for the granular proteins to access the pathogen.^{136,137} A mechanism of internalizing bacteria via the open canalicular system has also been proposed¹³⁸ (compare with Boukour and Cramer¹³⁹). Nonetheless, the platelet

Fc γ RIIa receptor can bind IgG complexes and allows platelets to clear these complexes from the circulation.¹⁴⁰ Internalization of IgG-coated particles results in platelet activation and the release of RANTES and sCD40L.¹⁴¹ Platelets opsonized by IgG can be destroyed by Fc-mediated platelet phagocytosis, contributing to the clearance of IgG-containing complexes from the circulation.^{142,143} More broadly, activated platelets expose phosphatidylserine, and neutrophils have been shown to phagocytose activated platelets in a clearance program involving phosphatidylserine and P-selectin.^{144–146}

Platelet Interactions with Viruses

Viruses have been observed to interact directly with platelets. Various viruses have been identified adsorbed to or inside platelets, including influenza virus,^{147,148} HIV,^{136,149,150} hepatitis C,^{151–153} and herpes simplex virus¹⁵⁴ as well as others such as vaccinia virus¹⁵⁵ and dengue virus.^{156–158} However, the interactions between viruses and platelets are less well characterized compared with those of gram-positive bacteria. This section describes the interaction of platelets with viruses, which are summarized in ►Fig. 6.

Platelet Receptors in Viral Pathogen Sensing

Several platelet receptors have been identified to mediate binding to viral particles,^{6,7,30,159} and are summarized in ►Table 3. Similarly to bacteria, IgG is important for the adhesion of viral particles to platelets, where IgG-coated particles can interact with the Fc γ RIIa receptor^{151,160–162} to be internalized into the platelet.¹⁴⁰ However, other antibody-dependent mechanisms that enhance viral binding to platelets are also described,¹⁵⁶ and platelets can further bind viruses in a receptor-independent manner.¹⁶³ For example, although the coxsackievirus and adenovirus receptor (CAR) is expressed on platelets, coxsackie B virus interaction with platelets has also been described independently of CAR and can result in P-selectin and phosphatidylserine exposure.¹⁶³ More broadly, β 3 integrins are important platelet-adhesion receptors, and these receptors appear to facilitate viral adhesion to platelets.^{18,65,164} Even though various receptors that are expressed on platelets have been implicated in viral adhesion and cell entry, the direct effect of this interaction on the platelet has not always been described.

Platelets can also detect viruses through TLRs. Platelet TLR2 can bind cytomegalovirus, which triggers platelet activation, degranulation, and the formation of platelet–leukocyte aggregates.¹⁶⁵ TLR7 recognizes the classical viral PAMP, single-stranded RNA.⁹² Platelets express functional TLR7, and activation via TLR7 leads to expression of CD40L and P-selectin, and P-selectin supports the adhesion of virally activated platelets to neutrophils.^{22,166} Moreover, platelet TLR7 mediates complement C3 release from platelets, which in turn leads to platelet–neutrophil aggregation and NET release by neutrophils.¹⁶⁷ Encephalomyocarditis virus has been shown to interact with platelet TLR7.¹⁶⁶ Platelet TLR9 recognizes unmethylated CpG islands found in bacterial and viral DNA, which also leads to P-selectin surface expression.^{92,168}




Fig. 6 Platelet interactions with viruses. Various platelet receptors can mediate binding to viral particles; however, the direct effect of this binding on platelets is less well described than for bacteria. Pattern recognition receptors recognize classical viral signals, and viral products also modulate platelet function. Platelets mediate viral attack by secreting virucidal proteins and by engulfing viral particles, as well as by interacting with immune cells and enhancing the immune response. Overall, platelets may be activated and aggregate, but also face apoptosis. Virus–platelet aggregates and platelets with a viral load are targeted by leukocytes, and platelets are ultimately cleared from the circulation (created with <https://biorender.com/>). CAR, coxsackievirus and adenovirus receptor; CCR/CXCR, chemokine receptor; CLEC, C-type lectin-like receptor; CR, complement receptor; DC-SIGN, dendritic cell-specific ICAM-grabbing nonintegrin; FcγRIIa, low-affinity immunoglobulin gamma Fc region receptor II-a; HIV, human immunodeficiency virus; Ig, immunoglobulin; RNA, ribonucleic acid; ROS, reactive oxygen species; Tat, trans-activator of transcription; TLR, toll-like receptor; vWF, von Willebrand factor.

Viral Products Affect Platelet Functions

Viruses secrete various products that modulate platelet function. The secreted HIV Tat protein directly interacts with platelets in a process requiring the platelet receptors CCR3 and β3 integrin as well as calcium influx. This leads to platelet activation and CD40L expression as well as micro-particle formation.⁶⁵ Indeed, platelet activation persists even in virologically suppressed HIV infection.¹⁶⁹ Viral enzymes such as neuraminidase can cause desialylation of platelet surface receptors,⁶ and desialylation might promote platelet clearance in the liver.^{170,171}

Platelets Mediate Antiviral Attack

The secretory products of platelets can also exert virucidal effects, including the inactivation of adenovirus, poliovirus and vaccinia virus,¹⁷² and HIV suppression.²⁰ Moreover, platelets exhibit phagocytic behavior toward viruses such as HIV and can form engulfing vacuoles that lead to granular components being secreted on the virus particle, as described for bacteria.¹³⁶ Indeed, intact HIV-1 particles enclosed in endocytic vesicles have been found in the open canalicular system.^{173,174} Recently, it has been proposed that platelets may also potentially phagocytose influenza virus.^{175,176} Platelets may then

Table 3 Platelet receptors that mediate viral binding

Virus	Viral component	Platelet receptors/host factors	Effect on platelet	References
Adenoviruses	Penton base (RGD ligand site)	Fibrinogen, laminin, vitronectin and vWF, α II β 3, α v β 3, CAR receptor	Platelet activation, platelet–leukocyte aggregate formation	30,218–221
Dengue virus		DC-SIGN	Platelet activation, platelet apoptosis	178,222,223
Ebola virus		DC-SIGN		224
Enterovirus echovirus 9 strain Barty	VP1 capsid protein (RGD ligand site)	α v β 3		225
Epstein–Barr virus		CR2	Platelet activation	226
Hantaviruses		α II β 3, α v β 3		227
Hepatitis C virus		GPVI		228
HIV	Mannose-type carbohydrates	CXCR4, DC-SIGN, CLEC2		174,229,230
Herpes simplex virus-1		α v β 3		231
Human parechovirus-1	VP1 capsid protein (RGD ligand site)	α v β 3		232
Lassa virus		DC-SIGN, Axl, Tyro3		233
Rotavirus	Spike protein VP4 (DGE ligand site)	α 2 β 1		234,235

Abbreviations: CLEC2, C-type lectin-like receptor 2; DC-SIGN, dendritic cell-specific ICAM-grabbing nonintegrin; DGE, Asp-Gly-Glu tripeptide; HIV, human immunodeficiency virus; RGD, Arg-Gly-Asp tripeptide; VP, viral (capsid) protein; vWF, von Willebrand factor.

cause disruption of viral integrity.¹⁷⁴ Overall, it has been suggested that internalization of viral particles by platelets may function to clear viruses from the circulation.¹⁷⁷

Viruses can cause the expression of P-selectin and phosphatidylserine exposure on platelets, and these components promote interactions with leukocytes as well as lead to phagocytosis of the platelet.^{163,178} Interaction between platelets and viruses can also lead to sequestration to the reticuloendothelial system of the liver, where virus–platelet aggregates can be taken up by Kupffer cells and degraded.¹⁷⁹ Spleen macrophages also assist in clearing platelets with a viral load.³⁰

Conclusion

Platelets are among the first cells to accumulate at sites of infection and inflammation, and can be considered as first responders to invading pathogens. Here, platelets have a key role in sensing and effecting the first wave of responses to microbial and viral threat.^{8,9} This is achieved by the inflammatory activity of platelets but also through direct antibacterial and antiviral actions that facilitate the clearance of pathogens from the circulation. Platelets are therefore represented at the interface of hemostasis, inflammation, and antimicrobial host defense. Their position at the crossroads of these processes emphasizes their role as signaling entities in infection and inflammation.

Various stimuli that are relevant to infection impinge on platelets, activating and forcing them to exert their effector actions. Recursive stimulation of activation receptors and

successive activation of bystander platelets intensify the host-defense functions of platelets even at threshold stoichiometric ratios of platelets to pathogens.¹⁸⁰ Platelets face inappropriate activation and immunological destruction, and are inevitably consumed by their participation in host defense. An inflammatory milieu can thereby drive platelet dysfunction. In this review, we emphasize that platelet dysfunction can arise as a general consequence of an exaggerated systemic (immune) response to infection. Increased platelet consumption and removal can lead to thrombocytopenia, which is frequently observed during infection. **Fig. 7** summarizes and links together the various processes we have discussed, to show a general mechanism of platelet depletion during infection.

Because of their largely protective role, lower platelet counts are associated with worse prognosis and greater likelihood of infection; however, platelets are also presented as having an ambivalent role in infections by possibly sheltering pathogens in certain cases.^{6,7,9,12,30,181} Nonetheless, in the context of impairment of the immune system, the functions of platelets become more important. Following the contribution of platelets to diverse immunological processes, dysregulation of platelet–leukocyte interactions, which are important for inflammatory and immune reactions, together with dysregulation of inflammatory mediators, establish an excessive and unbalanced systemic inflammatory response. In this context, platelets can contribute to pathophysiological processes and immunopathology, and become dysfunctional.

Achieving a balance between pro- and anti-inflammatory responses during infection is difficult to manipulate




Fig. 7 A generic large-scale cause for platelet dysfunction and depletion in infection. Platelets are intimately involved in the immune and host defense response to infection, where various stimuli challenge the platelet. Platelets operate in close connection with other cells and processes. Platelets are cells of one-time use, and their involvement in the diverse and interconnected processes against infection leads to their irreversible consumption. In the context of abundant stimulation, inappropriate and excessive activation of platelets results in their expenditure and exhaustion (created with <https://biorender.com/>). (Adapted from Yeaman.⁹) DAMP, damage-associated molecular pattern; NET, neutrophil extracellular trap; PAMP, pathogen-associated molecular pattern.

Table 4 Key points

- Platelets are versatile cells positioned at the interface of hemostasis, inflammation, and antimicrobial host defense, and their immune, antibacterial, and antiviral actions establish them as active participants in infection.
- By nature of their normal functioning, platelets are invariably and irreversibly expended in the processes to which they contribute.
- During infection, an onslaught of inflammatory and pathogen-derived stimuli can evoke and challenge platelets, leading to inappropriate activation, immunological destruction, and sequestration.
- In the context of a dysregulated host response to infection, platelets can experience overwhelming activation and, consequently, consumption, and this represents a generic large-scale mechanism for platelet depletion in infection.

effectively in a therapeutic context. Following from the diverse functions of platelets in infections, platelets are also placed at an interface between health and disease. Platelets are acutely affected by the surrounding environment. This, together with other characteristics of platelets such as their fast turnover, might position platelets as relevant signaling entities with clinical potential in disease tracking and targeting to evaluate or manage the course of infections. Although platelets are perhaps a lesser-known participant in the host-defense system, their large-scale depletion may cause significant health issues. Managing a generic depletion of platelets during the presence of infection should possibly be a more actively pursued clinical goal. The key points encapsulating the main ideas of this review are presented in ► **Table 4**.

Author Contribution Statement

M.P.: wrote paper, prepared figures; E.P.: wrote parts of the paper, study leader, and corresponding author. Both authors edited and reviewed the manuscript.

Conflicts of Interest

The authors have no competing interests to declare. Mr. Page is supported by the Skye Foundation and the Harry Crossley Foundation. Dr. Pretorius reports grants from the Medical Research Council of South Africa.

Acknowledgments

We thank the Medical Research Council of South Africa (Self-Initiated Research Program) for supporting our research. The funders had no role in the design and preparation of the manuscript or decision to publish.

References

- 1 Semple JW, Freedman J. Platelets and innate immunity. *Cell Mol Life Sci* 2010;67(04):499–511
- 2 Semple JW, Italiano JE Jr, Freedman J. Platelets and the immune continuum. *Nat Rev Immunol* 2011;11(04):264–274
- 3 Speth C, Löffler J, Krappmann S, Lass-Flörl C, Rambach G. Platelets as immune cells in infectious diseases. *Future Microbiol* 2013;8(11):1431–1451
- 4 Weyrich AS, Zimmerman GA. Platelets: signaling cells in the immune continuum. *Trends Immunol* 2004;25(09):489–495
- 5 Jenne CN, Kubes P. Platelets in inflammation and infection. *Platelets* 2015;26(04):286–292
- 6 Assinger A. Platelets and infection - an emerging role of platelets in viral infection. *Front Immunol* 2014;5:649
- 7 Hottz ED, Bozza FA, Bozza PT. Platelets in immune response to virus and immunopathology of viral infections. *Front Med (Lausanne)* 2018;5:121
- 8 Yeaman MR. Platelets in defense against bacterial pathogens. *Cell Mol Life Sci* 2010;67(04):525–544
- 9 Yeaman MR. Platelets: at the nexus of antimicrobial defence. *Nat Rev Microbiol* 2014;12(06):426–437
- 10 Fitzgerald JR, Foster TJ, Cox D. The interaction of bacterial pathogens with platelets. *Nat Rev Microbiol* 2006;4(06):445–457
- 11 Hamzeh-Cognasse H, Damien P, Chabert A, Pozzetto B, Cognasse F, Garraud O. Platelets and infections - complex interactions with bacteria. *Front Immunol* 2015;6:82
- 12 Cox D, Kerrigan SW, Watson SP. Platelets and the innate immune system: mechanisms of bacterial-induced platelet activation. *J Thromb Haemost* 2011;9(06):1097–1107
- 13 Wong CHY, Jenne CN, Petri B, Chrobok NL, Kubes P. Nucleation of platelets with blood-borne pathogens on Kupffer cells precedes other innate immunity and contributes to bacterial clearance. *Nat Immunol* 2013;14(08):785–792
- 14 Sullam PM, Frank U, Yeaman MR, Täuber MG, Bayer AS, Chambers HF. Effect of thrombocytopenia on the early course of streptococcal endocarditis. *J Infect Dis* 1993;168(04):910–914
- 15 Zhang X, Liu Y, Gao Y, et al. Inhibiting platelets aggregation could aggravate the acute infection caused by *Staphylococcus aureus*. *Platelets* 2011;22(03):228–236
- 16 Claushuis TAM, van Vught LA, Scicluna BP, et al; Molecular Diagnosis and Risk Stratification of Sepsis Consortium. Thrombocytopenia is associated with a dysregulated host response in critically ill sepsis patients. *Blood* 2016;127(24):3062–3072
- 17 Dewitte A, Lepreux S, Villeneuve J, et al. Blood platelets and sepsis pathophysiology: a new therapeutic prospect in critically ill patients? *Ann Intensive Care* 2017;7(01):115
- 18 Iannacone M, Sitia G, Isogawa M, et al. Platelets prevent IFN- α/β -induced lethal hemorrhage promoting CTL-dependent clearance of lymphocytic choriomeningitis virus. *Proc Natl Acad Sci U S A* 2008;105(02):629–634
- 19 Loria GD, Romagnoli PA, Moseley NB, Rucavado A, Altman JD. Platelets support a protective immune response to LCMV by preventing splenic necrosis. *Blood* 2013;121(06):940–950
- 20 Solomon Tsegaye T, Gnirß K, Rahe-Meyer N, et al. Platelet activation suppresses HIV-1 infection of T cells. *Retrovirology* 2013;10:48
- 21 D'Atri LP, Schattner M. Platelet toll-like receptors in thromboinflammation. *Front Biosci* 2017;22:1867–1883
- 22 Jenne CN. Platelets: crossroads of immunity and hemostasis. *Blood* 2014;124(05):671–672
- 23 Li Z, Delaney MK, O'Brien KA, Du X. Signaling during platelet adhesion and activation. *Arterioscler Thromb Vasc Biol* 2010;30(12):2341–2349
- 24 van Gils JM, Zwaginga JJ, Hordijk PL. Molecular and functional interactions among monocytes, platelets, and endothelial cells and their relevance for cardiovascular diseases. *J Leukoc Biol* 2009;85(02):195–204
- 25 Shannon O. Platelet interaction with bacterial toxins and secreted products. *Platelets* 2015;26(04):302–308
- 26 Zhang W, Nardi MA, Borkowsky W, Li Z, Karpatkin S. Role of molecular mimicry of hepatitis C virus protein with platelet GPIIIa in hepatitis C-related immunologic thrombocytopenia. *Blood* 2009;113(17):4086–4093
- 27 Aref S, Sleem T, El Menshawly N, et al. Antiplatelet antibodies contribute to thrombocytopenia associated with chronic hepatitis C virus infection. *Hematology* 2009;14(05):277–281
- 28 Olumuyiwa-Akeredolu OO, Page MJ, Soma P, Pretorius E. Platelets: emerging facilitators of cellular crosstalk in rheumatoid arthritis. *Nat Rev Rheumatol* 2019;15(04):237–248
- 29 Franchini M, Veneri D, Lippi G. Thrombocytopenia and infections. *Expert Rev Hematol* 2017;10(01):99–106
- 30 Flaujac C, Boukour S, Cramer-Bordé E. Platelets and viruses: an ambivalent relationship. *Cell Mol Life Sci* 2010;67(04):545–556
- 31 Larkin CM, Santos-Martinez M-J, Ryan T, Radomski MW. Sepsis-associated thrombocytopenia. *Thromb Res* 2016;141:11–16
- 32 Tosi MF. Innate immune responses to infection. *J Allergy Clin Immunol* 2005;116(02):241–249, quiz 250
- 33 McNicol A, Agpalza A, Jackson EC, Hamzeh-Cognasse H, Garraud O, Cognasse F. Streptococcus sanguinis-induced cytokine release from platelets. *J Thromb Haemost* 2011;9(10):2038–2049
- 34 Page AV, Liles WC. Biomarkers of endothelial activation/dysfunction in infectious diseases. *Virulence* 2013;4(06):507–516
- 35 Yeaman MR. The role of platelets in antimicrobial host defense. *Clin Infect Dis* 1997;25(05):951–968, quiz 969–970
- 36 Sugiyama MG, Gamage A, Zyla R, et al. Influenza virus infection induces platelet-endothelial adhesion which contributes to lung injury. *J Virol* 2015;90(04):1812–1823
- 37 Gawaz M, Langer H, May AE. Platelets in inflammation and atherogenesis. *J Clin Invest* 2005;115(12):3378–3384
- 38 Assinger A, Laky M, Schabbauer G, et al. Efficient phagocytosis of periodontopathogens by neutrophils requires plasma factors, platelets and TLR2. *J Thromb Haemost* 2011;9(04):799–809
- 39 Miedzobrodzki J, Panz T, Plonka PM, et al. Platelets augment respiratory burst in neutrophils activated by selected species of gram-positive or gram-negative bacteria. *Folia Histochem Cytobiol* 2008;46(03):383–388
- 40 Peters MJ, Dixon G, Kotowicz KT, Hatch DJ, Heyderman RS, Klein NJ. Circulating platelet-neutrophil complexes represent a subpopulation of activated neutrophils primed for adhesion, phagocytosis and intracellular killing. *Br J Haematol* 1999;106(02):391–399
- 41 Nagata K, Tsuji T, Todoroki N, et al. Activated platelets induce superoxide anion release by monocytes and neutrophils through P-selectin (CD62). *J Immunol* 1993;151(06):3267–3273

- 42 Jin R, Yu S, Song Z, et al. Soluble CD40 ligand stimulates CD40-dependent activation of the $\beta 2$ integrin Mac-1 and protein kinase C zeta (PKC ζ) in neutrophils: implications for neutrophil-platelet interactions and neutrophil oxidative burst. *PLoS One* 2013;8(06):e64631
- 43 Haselmayer P, Grosse-Hovest L, von Landenberg P, Schild H, Radsak MP. TREM-1 ligand expression on platelets enhances neutrophil activation. *Blood* 2007;110(03):1029–1035
- 44 Bouchon A, Facchetti F, Weigand MA, Colonna M. TREM-1 amplifies inflammation and is a crucial mediator of septic shock. *Nature* 2001;410(6832):1103–1107
- 45 Mohamadzadeh M, Coberley SS, Olinger GG, et al. Activation of triggering receptor expressed on myeloid cells-1 on human neutrophils by marburg and ebola viruses. *J Virol* 2006;80(14):7235–7244
- 46 Brinkmann V, Reichard U, Goosmann C, et al. Neutrophil extracellular traps kill bacteria. *Science* 2004;303(5663):1532–1535
- 47 McDonald B, Urrutia R, Yipp BG, Jenne CN, Kubes P. Intravascular neutrophil extracellular traps capture bacteria from the bloodstream during sepsis. *Cell Host Microbe* 2012;12(03):324–333
- 48 Ma AC, Kubes P. Platelets, neutrophils, and neutrophil extracellular traps (NETs) in sepsis. *J Thromb Haemost* 2008;6(03):415–420
- 49 Jenne CN, Wong CH, Zemp FJ, et al. Neutrophils recruited to sites of infection protect from virus challenge by releasing neutrophil extracellular traps. *Cell Host Microbe* 2013;13(02):169–180
- 50 Urban CF, Ermer D, Schmid M, et al. Neutrophil extracellular traps contain calprotectin, a cytosolic protein complex involved in host defense against *Candida albicans*. *PLoS Pathog* 2009;5(10):e1000639
- 51 Saitoh T, Komano J, Saitoh Y, et al. Neutrophil extracellular traps mediate a host defense response to human immunodeficiency virus-1. *Cell Host Microbe* 2012;12(01):109–116
- 52 Assinger A, Laky M, Badrnya S, Esfandeyari A, Volf I. Periodontopathogens induce expression of CD40L on human platelets via TLR2 and TLR4. *Thromb Res* 2012;130(03):e73–e78
- 53 Elzey BD, Tian J, Jensen RJ, et al. Platelet-mediated modulation of adaptive immunity. A communication link between innate and adaptive immune compartments. *Immunity* 2003;19(01):9–19
- 54 Sowa JM, Crist SA, Ratliff TL, Elzey BD. Platelet influence on T- and B-cell responses. *Arch Immunol Ther Exp (Warsz)* 2009;57(04):235–241
- 55 Elzey BD, Schmidt NW, Crist SA, et al. Platelet-derived CD154 enables T-cell priming and protection against *Listeria monocytogenes* challenge. *Blood* 2008;111(07):3684–3691
- 56 Kaneider NC, Kaser A, Tilg H, Ricevuti G, Wiedermann CJ. CD40 ligand-dependent maturation of human monocyte-derived dendritic cells by activated platelets. *Int J Immunopathol Pharmacol* 2003;16(03):225–231
- 57 Czapiga M, Kirk AD, Lekstrom-Himes J. Platelets deliver costimulatory signals to antigen-presenting cells: a potential bridge between injury and immune activation. *Exp Hematol* 2004;32(02):135–139
- 58 Kissel K, Berber S, Nockher A, Santos S, Bein G, Hackstein H. Human platelets target dendritic cell differentiation and production of proinflammatory cytokines. *Transfusion* 2006;46(05):818–827
- 59 Hamzeh-Cognasse H, Cognasse F, Palle S, et al. Direct contact of platelets and their released products exert different effects on human dendritic cell maturation. *BMC Immunol* 2008;9:54
- 60 Iannacone M, Sitia G, Isogawa M, et al. Platelets mediate cytotoxic T lymphocyte-induced liver damage. *Nat Med* 2005;11(11):1167–1169
- 61 Lang PA, Contaldo C, Georgiev P, et al. Aggravation of viral hepatitis by platelet-derived serotonin. *Nat Med* 2008;14(07):756–761
- 62 Verschoor A, Neuenhahn M, Navarini AA, et al. A platelet-mediated system for shuttling blood-borne bacteria to CD8 α + dendritic cells depends on glycoprotein GPIb and complement C3. *Nat Immunol* 2011;12(12):1194–1201
- 63 Ogura H, Kawasaki T, Tanaka H, et al. Activated platelets enhance microparticle formation and platelet-leukocyte interaction in severe trauma and sepsis. *J Trauma* 2001;50(05):801–809
- 64 Ge S, Hertel B, Emden SH, et al. Microparticle generation and leucocyte death in Shiga toxin-mediated HUS. *Nephrol Dial Transplant* 2012;27(07):2768–2775
- 65 Wang J, Zhang W, Nardi MA, Li Z. HIV-1 Tat-induced platelet activation and release of CD154 contribute to HIV-1-associated autoimmune thrombocytopenia. *J Thromb Haemost* 2011;9(03):562–573
- 66 Mayne E, Funderburg NT, Sieg SF, et al. Increased platelet and microparticle activation in HIV infection: upregulation of P-selectin and tissue factor expression. *J Acquir Immune Defic Syndr* 2012;59(04):340–346
- 67 Boilard E, Nigrovic PA, Larabee K, et al. Platelets amplify inflammation in arthritis via collagen-dependent microparticle production. *Science* 2010;327(5965):580–583
- 68 Nomura S. Function and clinical significance of platelet-derived microparticles. *Int J Hematol* 2001;74(04):397–404
- 69 Barry OP, Praticò D, Savani RC, FitzGerald GA. Modulation of monocyte-endothelial cell interactions by platelet microparticles. *J Clin Invest* 1998;102(01):136–144
- 70 Lo S-C, Hung C-Y, Lin D-T, Peng H-C, Huang T-F. Involvement of platelet glycoprotein Ib in platelet microparticle mediated neutrophil activation. *J Biomed Sci* 2006;13(06):787–796
- 71 Forlow SB, McEver RP, Nollert MU. Leukocyte-leukocyte interactions mediated by platelet microparticles under flow. *Blood* 2000;95(04):1317–1323
- 72 Merten M, Pakala R, Thiagarajan P, Benedict CR. Platelet microparticles promote platelet interaction with subendothelial matrix in a glycoprotein IIb/IIIa-dependent mechanism. *Circulation* 1999;99(19):2577–2582
- 73 Sprague DL, Elzey BD, Crist SA, Waldschmidt TJ, Jensen RJ, Ratliff TL. Platelet-mediated modulation of adaptive immunity: unique delivery of CD154 signal by platelet-derived membrane vesicles. *Blood* 2008;111(10):5028–5036
- 74 Nomura S, Fujita S, Nakanishi T, et al. Platelet-derived microparticles cause CD154-dependent activation of dendritic cells. *Platelets* 2012;23(01):81–82
- 75 Brown GT, McIntyre TM. Lipopolysaccharide signaling without a nucleus: kinase cascades stimulate platelet shedding of proinflammatory IL-1 β -rich microparticles. *J Immunol* 2011;186(09):5489–5496
- 76 Mause SF, von Hundelshausen P, Zerneck A, Koenen RR, Weber C. Platelet microparticles: a transcellular delivery system for RANTES promoting monocyte recruitment on endothelium. *Arterioscler Thromb Vasc Biol* 2005;25(07):1512–1518
- 77 Yin W, Ghebrehiwet B, Peerschke EI. Expression of complement components and inhibitors on platelet microparticles. *Platelets* 2008;19(03):225–233
- 78 Clawson CC, White JG. Platelet interaction with bacteria. I. Reaction phases and effects of inhibitors. *Am J Pathol* 1971;65(02):367–380
- 79 Clawson CC, Rao GH, White JG. Platelet interaction with bacteria. IV. Stimulation of the release reaction. *Am J Pathol* 1975;81(02):411–420
- 80 Ali RA, Wuescher LM, Worth RG. Platelets: essential components of the immune system. *Curr Trends Immunol* 2015;16:65–78
- 81 Kerrigan SW. The expanding field of platelet-bacterial interconnections. *Platelets* 2015;26(04):293–301
- 82 Mirlashari MR, Hagberg IA, Lyberg T. Platelet-platelet and platelet-leukocyte interactions induced by outer membrane vesicles from *N. meningitidis*. *Platelets* 2002;13(02):91–99
- 83 McNicol A. Bacteria-induced intracellular signalling in platelets. *Platelets* 2015;26(04):309–316

- 84 Arman M, Krauel K, Tilley DO, et al. Amplification of bacteria-induced platelet activation is triggered by FcγRIIA, integrin αIIbβ3, and platelet factor 4. *Blood* 2014;123(20):3166–3174
- 85 Naik UP. Bacteria exploit platelets. *Blood* 2014;123(20):3067–3068
- 86 Clemetson KJ, Clemetson JM, Proudfoot AE, Power CA, Baggiolini M, Wells TN. Functional expression of CCR1, CCR3, CCR4, and CXCR4 chemokine receptors on human platelets. *Blood* 2000;96(13):4046–4054
- 87 Gear AR, Camerini D. Platelet chemokines and chemokine receptors: linking hemostasis, inflammation, and host defense. *Microcirculation* 2003;10(3–4):335–350
- 88 Del Conde I, Cruz MA, Zhang H, López JA, Afshar-Kharghan V. Platelet activation leads to activation and propagation of the complement system. *J Exp Med* 2005;201(06):871–879
- 89 Peerschke EIB, Yin W, Ghebrehiwet B. Platelet mediated complement activation. *Adv Exp Med Biol* 2008;632:81–91
- 90 Cognasse F, Hamzeh H, Chavarin P, Acquart S, Genin C, Garraud O. Evidence of Toll-like receptor molecules on human platelets. *Immunol Cell Biol* 2005;83(02):196–198
- 91 Aslam R, Speck ER, Kim M, et al. Platelet Toll-like receptor expression modulates lipopolysaccharide-induced thrombocytopenia and tumor necrosis factor-α production in vivo. *Blood* 2006;107(02):637–641
- 92 Garraud O, Cognasse F. Platelet Toll-like receptor expression: the link between “danger” ligands and inflammation. *Inflamm Allergy Drug Targets* 2010;9(05):322–333
- 93 Andonegui G, Kerfoot SM, McNagny K, Ebbert KV, Patel KD, Kubes P. Platelets express functional Toll-like receptor-4. *Blood* 2005;106(07):2417–2423
- 94 Zhang G, Han J, Welch EJ, et al. Lipopolysaccharide stimulates platelet secretion and potentiates platelet aggregation via TLR4/MyD88 and the cGMP-dependent protein kinase pathway. *J Immunol* 2009;182(12):7997–8004
- 95 Berthet J, Damien P, Hamzeh-Cognasse H, et al. Human platelets can discriminate between various bacterial LPS isoforms via TLR4 signaling and differential cytokine secretion. *Clin Immunol* 2012;145(03):189–200
- 96 Cognasse F, Hamzeh-Cognasse H, Lafarge S, et al. Toll-like receptor 4 ligand can differentially modulate the release of cytokines by human platelets. *Br J Haematol* 2008;141(01):84–91
- 97 Cognasse F, Lafarge S, Chavarin P, Acquart S, Garraud O. Lipopolysaccharide induces sCD40L release through human platelets TLR4, but not TLR2 and TLR9. *Intensive Care Med* 2007;33(02):382–384
- 98 Zielinski T, Wachowicz B, Saluk-Juszczak J, Kaca W. The generation of superoxide anion in blood platelets in response to different forms of *Proteus mirabilis* lipopolysaccharide: effects of staurosporin, wortmannin, and indomethacin. *Thromb Res* 2001;103(02):149–155
- 99 Werts C, Tapping RI, Mathison JC, et al. Leptospiral lipopolysaccharide activates cells through a TLR2-dependent mechanism. *Nat Immunol* 2001;2(04):346–352
- 100 Darveau RP, Pham TT, Lemley K, et al. *Porphyromonas gingivalis* lipopolysaccharide contains multiple lipid A species that functionally interact with both toll-like receptors 2 and 4. *Infect Immun* 2004;72(09):5041–5051
- 101 Erridge C, Pridmore A, Eley A, Stewart J, Poxton IR. Lipopolysaccharides of *Bacteroides fragilis*, *Chlamydia trachomatis* and *Pseudomonas aeruginosa* signal via toll-like receptor 2. *J Med Microbiol* 2004;53(Pt 8):735–740
- 102 Keane C, Tilley D, Cunningham A, et al. Invasive *Streptococcus pneumoniae* trigger platelet activation via Toll-like receptor 2. *J Thromb Haemost* 2010;8(12):2757–2765
- 103 Blair P, Rex S, Vitseva O, et al. Stimulation of Toll-like receptor 2 in human platelets induces a thromboinflammatory response through activation of phosphoinositide 3-kinase. *Circ Res* 2009;104(03):346–354
- 104 Kälvegren H, Skoglund C, Helldahl C, Lerm M, Grenegård M, Bengtsson T. Toll-like receptor 2 stimulation of platelets is mediated by purinergic P2X1-dependent Ca²⁺ mobilisation, cyclooxygenase and purinergic P2Y1 and P2Y12 receptor activation. *Thromb Haemost* 2010;103(02):398–407
- 105 Ward JR, Bingle L, Judge HM, et al. Agonists of toll-like receptor (TLR)2 and TLR4 are unable to modulate platelet activation by adenosine diphosphate and platelet activating factor. *Thromb Haemost* 2005;94(04):831–838
- 106 Czapiga M, Gao JL, Kirk A, Lekstrom-Himes J. Human platelets exhibit chemotaxis using functional N-formyl peptide receptors. *Exp Hematol* 2005;33(01):73–84
- 107 Loubakos A, Yuan YP, Jenkins AL, et al. Activation of protease-activated receptors by gingipains from *Porphyromonas gingivalis* leads to platelet aggregation: a new trait in microbial pathogenicity. *Blood* 2001;97(12):3790–3797
- 108 Pham K, Feik D, Hammond BF, Rams TE, Whitaker EJ. Aggregation of human platelets by gingipain-R from *Porphyromonas gingivalis* cells and membrane vesicles. *Platelets* 2002;13(01):21–30
- 109 Bhakdi S, Muhly M, Mannhardt U, et al. Staphylococcal alpha toxin promotes blood coagulation via attack on human platelets. *J Exp Med* 1988;168(02):527–542
- 110 Arvand M, Bhakdi S, Dahlbäck B, Preissner KT. Staphylococcus aureus alpha-toxin attack on human platelets promotes assembly of the prothrombinase complex. *J Biol Chem* 1990;265(24):14377–14381
- 111 Hu H, Armstrong PCJ, Khalil E, et al. GPVI and GPIbα mediate staphylococcal superantigen-like protein 5 (SSL5) induced platelet activation and direct toward glycans as potential inhibitors. *PLoS One* 2011;6(04):e19190
- 112 de Haas CJC, Weeterings C, Vughs MM, de Groot PG, Van Strijp JA, Lisman T. Staphylococcal superantigen-like 5 activates platelets and supports platelet adhesion under flow conditions, which involves glycoprotein Ibα and αIIbβ3. *J Thromb Haemost* 2009;7(11):1867–1874
- 113 Niemann S, Bertling A, Brodde MF, et al. Pantone-Valentine leukocidin associated with *S. aureus* osteomyelitis activates platelets via neutrophil secretion products. *Sci Rep* 2018;8(01):2185
- 114 Bertling A, Niemann S, Hussain M, et al. Staphylococcal extracellular adherence protein induces platelet activation by stimulation of thiol isomerases. *Arterioscler Thromb Vasc Biol* 2012;32(08):1979–1990
- 115 Palma M, Shannon O, Quezada HC, Berg A, Flock JI. Extracellular fibrinogen-binding protein, Efb, from *Staphylococcus aureus* blocks platelet aggregation due to its binding to the alpha-chain. *J Biol Chem* 2001;276(34):31691–31697
- 116 Shannon O, Flock JI. Extracellular fibrinogen binding protein, Efb, from *Staphylococcus aureus* binds to platelets and inhibits platelet aggregation. *Thromb Haemost* 2004;91(04):779–789
- 117 Shannon O, Uekötter A, Flock JI. Extracellular fibrinogen binding protein, Efb, from *Staphylococcus aureus* as an antiplatelet agent in vivo. *Thromb Haemost* 2005;93(05):927–931
- 118 Tran U, Boyle T, Shupp JW, Hammamieh R, Jett M. Staphylococcal enterotoxin B initiates protein kinase C translocation and eicosanoid metabolism while inhibiting thrombin-induced aggregation in human platelets. *Mol Cell Biochem* 2006;288(1–2):171–178
- 119 Waller AK, Sage T, Kumar C, Carr T, Gibbins JM, Clarke SR. *Staphylococcus aureus* lipoteichoic acid inhibits platelet activation and thrombus formation via the Paf receptor. *J Infect Dis* 2013;208(12):2046–2057
- 120 Beachey EH, Chiang TM, Ofek I, Kang AH. Interaction of lipoteichoic acid of group A streptococci with human platelets. *Infect Immun* 1977;16(02):649–654
- 121 Wu BQ, Zhi MJ, Liu H, Huang J, Zhou YQ, Zhang TT. Inhibitory effects of lipoteichoic acid from *Staphylococcus aureus* on platelet function and platelet-monocyte aggregation. *Inflamm Res* 2011;60(08):775–782

- 122 Sheu JR, Lee CR, Lin CH, et al. Mechanisms involved in the antiplatelet activity of *Staphylococcus aureus* lipoteichoic acid in human platelets. *Thromb Haemost* 2000;83(05):777–784
- 123 Chugh TD, Burns GJ, Shuhaiber HJ, Bahr GM. Adherence of *Staphylococcus epidermidis* to fibrin-platelet clots in vitro mediated by lipoteichoic acid. *Infect Immun* 1990;58(02):315–319
- 124 Vanassche T, Kauskot A, Verhaegen J, et al. Fibrin formation by staphylothrombin facilitates *Staphylococcus aureus*-induced platelet aggregation. *Thromb Haemost* 2012;107(06):1107–1121
- 125 Suehiro A, Oura Y, Ueda M, Kakishita E. Inhibitory effect of staphylokinase on platelet aggregation. *Thromb Haemost* 1993;70(05):834–837
- 126 Kraemer BF, Campbell RA, Schwertz H, et al. Bacteria differentially induce degradation of Bcl-xL, a survival protein, by human platelets. *Blood* 2012;120(25):5014–5020
- 127 Towhid ST, Nega M, Schmidt EM, et al. Stimulation of platelet apoptosis by peptidoglycan from *Staphylococcus aureus* 113. *Apoptosis* 2012;17(09):998–1008
- 128 Bhakdi S, Tranum-Jensen J. Alpha-toxin of *Staphylococcus aureus*. *Microbiol Rev* 1991;55(04):733–751
- 129 Guo Y-L, Liu D-Q, Bian Z, Zhang C-Y, Zen K. Down-regulation of platelet surface CD47 expression in *Escherichia coli* O157:H7 infection-induced thrombocytopenia. *PLoS One* 2009;4(09):e7131
- 130 Johnson MK, Boese-Marrazzo D, Pierce WA Jr. Effects of pneumolysin on human polymorphonuclear leukocytes and platelets. *Infect Immun* 1981;34(01):171–176
- 131 Bayer AS, Ramos MD, Menzies BE, Yeaman MR, Shen AJ, Cheung AL. Hyperproduction of alpha-toxin by *Staphylococcus aureus* results in paradoxically reduced virulence in experimental endocarditis: a host defense role for platelet microbicidal proteins. *Infect Immun* 1997;65(11):4652–4660
- 132 Bryant AE, Bayer CR, Chen RY, Guth PH, Wallace RJ, Stevens DL. Vascular dysfunction and ischemic destruction of tissue in *Streptococcus pyogenes* infection: the role of streptolysin O-induced platelet/neutrophil complexes. *J Infect Dis* 2005;192(06):1014–1022
- 133 Bryant AE, Chen RY, Nagata Y, et al. Clostridial gas gangrene. II. Phospholipase C-induced activation of platelet gplIb/IIIa mediates vascular occlusion and myonecrosis in *Clostridium perfringens* gas gangrene. *J Infect Dis* 2000;182(03):808–815
- 134 Khan SY, Kelher MR, Heal JM, et al. Soluble CD40 ligand accumulates in stored blood components, primes neutrophils through CD40, and is a potential cofactor in the development of transfusion-related acute lung injury. *Blood* 2006;108(07):2455–2462
- 135 Chakrabarti S, Varghese S, Vitseva O, Tanriverdi K, Freedman JE. CD40 ligand influences platelet release of reactive oxygen intermediates. *Arterioscler Thromb Vasc Biol* 2005;25(11):2428–2434
- 136 Youssefian T, Drouin A, Massé JM, Guichard J, Cramer EM. Host defense role of platelets: engulfment of HIV and *Staphylococcus aureus* occurs in a specific subcellular compartment and is enhanced by platelet activation. *Blood* 2002;99(11):4021–4029
- 137 Li X, Iwai T, Nakamura H, et al. An ultrastructural study of *Porphyromonas gingivalis*-induced platelet aggregation. *Thromb Res* 2008;122(06):810–819
- 138 White JG. Platelets are coverocytes, not phagocytes: uptake of bacteria involves channels of the open canalicular system. *Platelets* 2005;16(02):121–131
- 139 Boukour S, Cramer EM. Platelet interaction with bacteria. *Platelets* 2005;16(3–4):215–217
- 140 Worth RG, Chien CD, Chien P, Reilly MP, McKenzie SE, Schreiber AD. Platelet FcγRIIA binds and internalizes IgG-containing complexes. *Exp Hematol* 2006;34(11):1490–1495
- 141 Antczak AJ, Vieth JA, Singh N, Worth RG. Internalization of IgG-coated targets results in activation and secretion of soluble CD40 ligand and RANTES by human platelets. *Clin Vaccine Immunol* 2011;18(02):210–216
- 142 Semple JW, Aslam R, Kim M, Speck ER, Freedman J. Platelet-bound lipopolysaccharide enhances Fc receptor-mediated phagocytosis of IgG-opsonized platelets. *Blood* 2007;109(11):4803–4805
- 143 Huang Z-Y, Chien P, Indik ZK, Schreiber AD. Human platelet FcγRIIA and phagocytes in immune-complex clearance. *Mol Immunol* 2011;48(04):691–696
- 144 Maugeri N, Rovere-Querini P, Evangelista V, et al. Neutrophils phagocytose activated platelets in vivo: a phosphatidylserine, P-selectin, and β2 integrin-dependent cell clearance program. *Blood* 2009;113(21):5254–5265
- 145 Manfredi AA, Rovere-Querini P, Maugeri N. Dangerous connections: neutrophils and the phagocytic clearance of activated platelets. *Curr Opin Hematol* 2010;17(01):3–8
- 146 Maugeri N, Cattaneo M, Rovere-Querini P, Manfredi AA. Platelet clearance by circulating leukocytes: a rare event or a determinant of the “immune continuum”? *Platelets* 2014;25(03):224–225
- 147 Terada H, Baldini M, Ebbe S, Madoff MA. Interaction of influenza virus with blood platelets. *Blood* 1966;28(02):213–228
- 148 Danon D, Jerushalmy Z, De Vries A. Incorporation of influenza virus in human blood platelets in vitro. Electron microscopical observation. *Virology* 1959;9(04):719–722
- 149 Zucker-Franklin D, Seremetis S, Zheng ZY. Internalization of human immunodeficiency virus type I and other retroviruses by megakaryocytes and platelets. *Blood* 1990;75(10):1920–1923
- 150 Beck Z, Jagodzinski LL, Eller MA, et al. Platelets and erythrocyte-bound platelets bind infectious HIV-1 in plasma of chronically infected patients. *PLoS One* 2013;8(11):e81002
- 151 Hamaia S, Li C, Allain J-P. The dynamics of hepatitis C virus binding to platelets and 2 mononuclear cell lines. *Blood* 2001;98(08):2293–2300
- 152 Pugliese A, Gennero L, Cutufia M, et al. HCV infective virions can be carried by human platelets. *Cell Biochem Funct* 2004;22(06):353–358
- 153 de Almeida AJ, Campos-de-Magalhães M, Brandão-Mello CE, et al. Detection of hepatitis C virus in platelets: evaluating its relationship to antiviral therapy outcome. *Hepatogastroenterology* 2009;56(90):429–436
- 154 Forghani B, Schmidt NJ. Association of herpes simplex virus with platelets of experimentally infected mice. *Arch Virol* 1983;76(03):269–274
- 155 Bik T, Sarov I, Livne A. Interaction between vaccinia virus and human blood platelets. *Blood* 1982;59(03):482–487
- 156 Wang S, He R, Patarapotikul J, Innis BL, Anderson R. Antibody-enhanced binding of dengue-2 virus to human platelets. *Virology* 1995;213(01):254–257
- 157 Ghosh K, Gangodkar S, Jain P, et al. Imaging the interaction between dengue 2 virus and human blood platelets using atomic force and electron microscopy. *J Electron Microscop (Tokyo)* 2008;57(03):113–118
- 158 Noisakran S, Gibbons RV, Songprakhon P, et al. Detection of dengue virus in platelets isolated from dengue patients. *Southeast Asian J Trop Med Public Health* 2009;40(02):253–262
- 159 Alonso AL, Cox D. Platelet interactions with viruses and parasites. *Platelets* 2015;26(04):317–323
- 160 Boilard E, Paré G, Rousseau M, et al. Influenza virus H1N1 activates platelets through FcγRIIA signaling and thrombin generation. *Blood* 2014;123(18):2854–2863
- 161 Moi ML, Lim CK, Takasaki T, Kurane I. Involvement of the FcγRIIA cytoplasmic domain in antibody-dependent enhancement of dengue virus infection. *J Gen Virol* 2010;91(Pt 1):103–111
- 162 Rodenhuis-Zybert IA, van der Schaar HM, da Silva Voorham JM, et al. Immature dengue virus: a veiled pathogen? *PLoS Pathog* 2010;6(01):e1000718

- 163 Negrotto S, Jaquenod de Giusti C, Rivadeneira L, et al. Platelets interact with coxsackieviruses B and have a critical role in the pathogenesis of virus-induced myocarditis. *J Thromb Haemost* 2015;13(02):271–282
- 164 Mackow ER, Gavrilovskaya IN. Cellular receptors and hantavirus pathogenesis. *Curr Top Microbiol Immunol* 2001;256:91–115
- 165 Assinger A, Kral JB, Yaiw KC, et al. Human cytomegalovirus-platelet interaction triggers toll-like receptor 2-dependent proinflammatory and proangiogenic responses. *Arterioscler Thromb Vasc Biol* 2014;34(04):801–809
- 166 Koupenova M, Vitseva O, MacKay CR, et al. Platelet-TLR7 mediates host survival and platelet count during viral infection in the absence of platelet-dependent thrombosis. *Blood* 2014;124(05):791–802
- 167 Koupenova M, Corkrey HA, Vitseva O, et al. The role of platelets in mediating a response to human influenza infection. *Nat Commun* 2019;10(01):1780
- 168 Thon JN, Peters CG, Machlus KR, et al. T granules in human platelets function in TLR9 organization and signaling. *J Cell Biol* 2012;198(04):561–574
- 169 Mesquita EC, Hottz ED, Amancio RT, et al. Persistent platelet activation and apoptosis in virologically suppressed HIV-infected individuals. *Sci Rep* 2018;8(01):14999
- 170 Li J, van der Wal DE, Zhu G, et al. Desialylation is a mechanism of Fc-independent platelet clearance and a therapeutic target in immune thrombocytopenia. *Nat Commun* 2015;6:7737
- 171 Sørensen AL, Rumjantseva V, Nayeb-Hashemi S, et al. Role of sialic acid for platelet life span: exposure of beta-galactose results in the rapid clearance of platelets from the circulation by asialoglycoprotein receptor-expressing liver macrophages and hepatocytes. *Blood* 2009;114(08):1645–1654
- 172 Maurice A, Marchand-Arvier M, Edert D, Le Faou A, Gondrexon G, Vigneron C. The virucidal effect of platelet concentrates: preliminary study and first conclusions. *Platelets* 2002;13(04):219–222
- 173 Chabert A, Hamzeh-Cognasse H, Pozzetto B, et al. Human platelets and their capacity of binding viruses: meaning and challenges? *BMC Immunol* 2015;16:26
- 174 Boukour S, Massé JM, Bénit L, Dubart-Kupperschmitt A, Cramer EM. Lentivirus degradation and DC-SIGN expression by human platelets and megakaryocytes. *J Thromb Haemost* 2006;4(02):426–435
- 175 Jansen G, Low H, van den Brand J, van Riel D, van der Vries E. Uptake of influenza virus by platelets occurs via phagocytosis. *Blood* 2017;130(Suppl 1):4834
- 176 Jansen AJG, Low HZ, van den Brand J, van Riel D, Osterhaus A, van der Vries E. Platelets can phagocytose influenza virus which may contribute to the occurrence of thrombocytopenia during influenza infection. *Blood* 2016;128(22):1358
- 177 Kullaya VI, de Mast Q, van der Ven A, et al. Platelets modulate innate immune response against human respiratory syncytial virus in vitro. *Viral Immunol* 2017;30(08):576–581
- 178 Alonzo MT, Lacuesta TL, Dimaano EM, et al. Platelet apoptosis and apoptotic platelet clearance by macrophages in secondary dengue virus infections. *J Infect Dis* 2012;205(08):1321–1329
- 179 Stone D, Liu Y, Shayakhmetov D, Li Z-Y, Ni S, Lieber A. Adenovirus-platelet interaction in blood causes virus sequestration to the reticuloendothelial system of the liver. *J Virol* 2007;81(09):4866–4871
- 180 Trier DA, Gank KD, Kupferwasser D, et al. Platelet anti-staphylococcal responses occur through P2X1 and P2Y12 receptor-induced activation and kinocidin release. *Infect Immun* 2008;76(12):5706–5713
- 181 White JG. Why human platelets fail to kill bacteria. *Platelets* 2006;17(03):191–200
- 182 Coburn J, Leong JM, Erban JK. Integrin alpha IIb beta 3 mediates binding of the Lyme disease agent *Borrelia burgdorferi* to human platelets. *Proc Natl Acad Sci U S A* 1993;90(15):7059–7063
- 183 Kälvegren H, Majeed M, Bengtsson T. Chlamydia pneumoniae binds to platelets and triggers P-selectin expression and aggregation: a causal role in cardiovascular disease? *Arterioscler Thromb Vasc Biol* 2003;23(09):1677–1683
- 184 Byrne MF, Kerrigan SW, Corcoran PA, et al. *Helicobacter pylori* binds von Willebrand factor and interacts with GPIb to induce platelet aggregation. *Gastroenterology* 2003;124(07):1846–1854
- 185 Naito M, Sakai E, Shi Y, et al. Porphyromonas gingivalis-induced platelet aggregation in plasma depends on Hgp44 adhesin but not Rgp proteinase. *Mol Microbiol* 2006;59(01):152–167
- 186 Pietroccola G, Schubert A, Visai L, et al. FbsA, a fibrinogen-binding protein from *Streptococcus agalactiae*, mediates platelet aggregation. *Blood* 2005;105(03):1052–1059
- 187 Kerrigan SW, Clarke N, Loughman A, Meade G, Foster TJ, Cox D. Molecular basis for *Staphylococcus aureus*-mediated platelet aggregate formation under arterial shear in vitro. *Arterioscler Thromb Vasc Biol* 2008;28(02):335–340
- 188 Loughman A, Fitzgerald JR, Brennan MP, et al. Roles for fibrinogen, immunoglobulin and complement in platelet activation promoted by *Staphylococcus aureus* clumping factor A. *Mol Microbiol* 2005;57(03):804–818
- 189 Miajlovic H, Loughman A, Brennan M, Cox D, Foster TJ. Both complement- and fibrinogen-dependent mechanisms contribute to platelet aggregation mediated by *Staphylococcus aureus* clumping factor B. *Infect Immun* 2007;75(07):3335–3343
- 190 Fitzgerald JR, Loughman A, Keane F, et al. Fibronectin-binding proteins of *Staphylococcus aureus* mediate activation of human platelets via fibrinogen and fibronectin bridges to integrin GPIIb/IIIa and IgG binding to the Fc gammaRIIa receptor. *Mol Microbiol* 2006;59(01):212–230
- 191 O'Brien L, Kerrigan SW, Kaw G, et al. Multiple mechanisms for the activation of human platelet aggregation by *Staphylococcus aureus*: roles for the clumping factors ClfA and ClfB, the serine-aspartate repeat protein SdrE and protein A. *Mol Microbiol* 2002;44(04):1033–1044
- 192 Herrmann M, Suchard SJ, Boxer LA, Waldvogel FA, Lew PD. Thrombospondin binds to *Staphylococcus aureus* and promotes staphylococcal adherence to surfaces. *Infect Immun* 1991;59(01):279–288
- 193 Herrmann M, Lai QJ, Albrecht RM, Mosher DF, Proctor RA. Adhesion of *Staphylococcus aureus* to surface-bound platelets: role of fibrinogen/fibrin and platelet integrins. *J Infect Dis* 1993;167(02):312–322
- 194 Bayer AS, Sullam PM, Ramos M, Li C, Cheung AL, Yeaman MR. *Staphylococcus aureus* induces platelet aggregation via a fibrinogen-dependent mechanism which is independent of principal platelet glycoprotein IIb/IIIa fibrinogen-binding domains. *Infect Immun* 1995;63(09):3634–3641
- 195 Hawiger J, Steckley S, Hammond D, et al. Staphylococci-induced human platelet injury mediated by protein A and immunoglobulin G Fc fragment receptor. *J Clin Invest* 1979;64(04):931–937
- 196 Nguyen T, Ghebrehiwet B, Peerschke EIB. *Staphylococcus aureus* protein A recognizes platelet gC1qR/p33: a novel mechanism for staphylococcal interactions with platelets. *Infect Immun* 2000;68(04):2061–2068
- 197 Zapotoczna M, Jevnikar Z, Miajlovic H, Kos J, Foster TJ. Iron-regulated surface determinant B (IsdB) promotes *Staphylococcus aureus* adherence to and internalization by non-phagocytic human cells. *Cell Microbiol* 2013;15(06):1026–1041
- 198 Miajlovic H, Zapotoczna M, Geoghegan JA, Kerrigan SW, Speziale P, Foster TJ. Direct interaction of iron-regulated surface determinant IsdB of *Staphylococcus aureus* with the GPIIb/IIIa receptor on platelets. *Microbiology* 2010;156(Pt 3):920–928
- 199 O'Seaghda M, van Schooten CJ, Kerrigan SW, et al. *Staphylococcus aureus* protein A binding to von Willebrand factor A1 domain is mediated by conserved IgG binding regions. *FEBS J* 2006;273(21):4831–4841

- 200 Hartleib J, Köhler N, Dickinson RB, et al. Protein A is the von Willebrand factor binding protein on *Staphylococcus aureus*. *Blood* 2000;96(06):2149–2156
- 201 Sjöbring U, Ringdahl U, Ruggeri ZM. Induction of platelet thrombi by bacteria and antibodies. *Blood* 2002;100(13):4470–4477
- 202 Brennan MP, Loughman A, Devocelle M, et al. Elucidating the role of *Staphylococcus epidermidis* serine-aspartate repeat protein G in platelet activation. *J Thromb Haemost* 2009;7(08):1364–1372
- 203 Petersen HJ, Keane C, Jenkinson HF, et al. Human platelets recognize a novel surface protein, PadA, on *Streptococcus gordonii* through a unique interaction involving fibrinogen receptor GPIIb/IIIa. *Infect Immun* 2010;78(01):413–422
- 204 Keane C, Petersen H, Reynolds K, et al. Mechanism of outside-in α Ib β 3-mediated activation of human platelets by the colonizing bacterium, *Streptococcus gordonii*. *Arterioscler Thromb Vasc Biol* 2010;30(12):2408–2415
- 205 Takamatsu D, Bensing BA, Cheng H, et al. Binding of the *Streptococcus gordonii* surface glycoproteins GspB and Hsa to specific carbohydrate structures on platelet membrane glycoprotein Ibalpha. *Mol Microbiol* 2005;58(02):380–392
- 206 Kerrigan SW, Jakubovics NS, Keane C, et al. Role of *Streptococcus gordonii* surface proteins SspA/SspB and Hsa in platelet function. *Infect Immun* 2007;75(12):5740–5747
- 207 Mitchell J, Tristan A, Foster TJ. Characterization of the fibrinogen-binding surface protein Fbl of *Staphylococcus lugdunensis*. *Microbiology* 2004;150(Pt 11):3831–3841
- 208 Seo HS, Xiong YQ, Mitchell J, Seepersaud R, Bayer AS, Sullam PM. Bacteriophage lysin mediates the binding of *Streptococcus mitis* to human platelets through interaction with fibrinogen. *PLoS Pathog* 2010;6(08):e1001047
- 209 Mitchell J, Sullam PM. *Streptococcus mitis* phage-encoded adhesins mediate attachment to alpha2-8-linked sialic acid residues on platelet membrane gangliosides. *Infect Immun* 2009;77(08):3485–3490
- 210 Tilley DO, Arman M, Smolenski A, et al. Glycoprotein Iba and FcγRIIa play key roles in platelet activation by the colonizing bacterium, *Streptococcus oralis*. *J Thromb Haemost* 2013;11(05):941–950
- 211 Anderson R, Feldman C. Review manuscript: mechanisms of platelet activation by the pneumococcus and the role of platelets in community-acquired pneumonia. *J Infect* 2017;75(06):473–485
- 212 Binsker U, Kohler TP, Krauel K, Kohler S, Schwertz H, Hammerschmidt S. Pneumococcal adhesins PavB and PspC are important for the interplay with human thrombospondin-1. *J Biol Chem* 2015;290(23):14542–14555
- 213 Binsker U, Kohler TP, Krauel K, et al. Serotype 3 pneumococci sequester platelet-derived human thrombospondin-1 via the adhesin and immune evasion protein Hic. *J Biol Chem* 2017;292(14):5770–5783
- 214 Svensson L, Baumgarten M, Mörgelin M, Shannon O. Platelet activation by *Streptococcus pyogenes* leads to entrapment in platelet aggregates, from which bacteria subsequently escape. *Infect Immun* 2014;82(10):4307–4314
- 215 Ford I, Douglas CW, Cox D, Rees DG, Heath J, Preston FE. The role of immunoglobulin G and fibrinogen in platelet aggregation by *Streptococcus sanguis*. *Br J Haematol* 1997;97(04):737–746
- 216 Plummer C, Wu H, Kerrigan SW, Meade G, Cox D, Ian Douglas CW. A serine-rich glycoprotein of *Streptococcus sanguis* mediates adhesion to platelets via GPIb. *Br J Haematol* 2005;129(01):101–109
- 217 Kerrigan SW, Douglas I, Wray A, et al. A role for glycoprotein Ib in *Streptococcus sanguis*-induced platelet aggregation. *Blood* 2002;100(02):509–516
- 218 Zhang Y, Bergelson JM. Adenovirus receptors. *J Virol* 2005;79(19):12125–12131
- 219 Eggerman TL, Mondoro TH, Lozier JN, Vostal JG. Adenoviral vectors do not induce, inhibit, or potentiate human platelet aggregation. *Hum Gene Ther* 2002;13(01):125–128
- 220 Jin YY, Yu XN, Qu ZY, et al. Adenovirus type 3 induces platelet activation in vitro. *Mol Med Rep* 2014;9(01):370–374
- 221 Othman M, Labelle A, Mazzetti I, Elbatarny HS, Lillcrap D. Adenovirus-induced thrombocytopenia: the role of von Willebrand factor and P-selectin in mediating accelerated platelet clearance. *Blood* 2007;109(07):2832–2839
- 222 Simon AY, Sutherland MR, Prydzial ELG. Dengue virus binding and replication by platelets. *Blood* 2015;126(03):378–385
- 223 Hottz ED, Oliveira MF, Nunes PC, et al. Dengue induces platelet activation, mitochondrial dysfunction and cell death through mechanisms that involve DC-SIGN and caspases. *J Thromb Haemost* 2013;11(05):951–962
- 224 Alvarez CP, Lasala F, Carrillo J, Muñoz O, Corbí AL, Delgado R. C-type lectins DC-SIGN and L-SIGN mediate cellular entry by Ebola virus in cis and in trans. *J Virol* 2002;76(13):6841–6844
- 225 Nelsen-Salz B, Eggers HJ, Zimmermann H. Integrin alpha(v)beta3 (vitronectin receptor) is a candidate receptor for the virulent echovirus 9 strain Barty. *J Gen Virol* 1999;80(Pt 9):2311–2313
- 226 Nunez D, Charriaut-Marlangue C, Barel M, Benveniste J, Frade R. Activation of human platelets through gp140, the C3d/EBV receptor (CR2). *Eur J Immunol* 1987;17(04):515–520
- 227 Gavrilovskaya IN, Gorbunova EE, Mackow ER. Pathogenic hantaviruses direct the adherence of quiescent platelets to infected endothelial cells. *J Virol* 2010;84(09):4832–4839
- 228 Zahn A, Jennings N, Ouwehand WH, Allain JP. Hepatitis C virus interacts with human platelet glycoprotein VI. *J Gen Virol* 2006;87(Pt 8):2243–2251
- 229 Kowalska MA, Ratajczak J, Hoxie J, et al. Megakaryocyte precursors, megakaryocytes and platelets express the HIV co-receptor CXCR4 on their surface: determination of response to stromal-derived factor-1 by megakaryocytes and platelets. *Br J Haematol* 1999;104(02):220–229
- 230 Chaipan C, Soilleux EJ, Simpson P, et al. DC-SIGN and CLEC-2 mediate human immunodeficiency virus type 1 capture by platelets. *J Virol* 2006;80(18):8951–8960
- 231 Gianni T, Leoni V, Chesnokova LS, Hutt-Fletcher LM, Campadelli-Fiume G. α v β 3-integrin is a major sensor and activator of innate immunity to herpes simplex virus-1. *Proc Natl Acad Sci U S A* 2012;109(48):19792–19797
- 232 Triantafilou K, Triantafilou M, Takada Y, Fernandez N. Human parechovirus 1 utilizes integrins alphavbeta3 and alphavbeta1 as receptors. *J Virol* 2000;74(13):5856–5862
- 233 Shimojima M, Ströher U, Ebihara H, Feldmann H, Kawaoka Y. Identification of cell surface molecules involved in dystroglycan-independent Lassa virus cell entry. *J Virol* 2012;86(04):2067–2078
- 234 Coulson BS, Londrigan SL, Lee DJ. Rotavirus contains integrin ligand sequences and a disintegrin-like domain that are implicated in virus entry into cells. *Proc Natl Acad Sci U S A* 1997;94(10):5389–5394
- 235 Fleming FE, Graham KL, Takada Y, Coulson BS. Determinants of the specificity of rotavirus interactions with the alpha2beta1 integrin. *J Biol Chem* 2011;286(08):6165–6174